SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Fauci AS, Katz P, Haynes BF, Wolff SM.Cyclophosphamide therapy of severe systemic necrotizing vasculitis.N Engl J Med1979;301:2358.
  • 2
    Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al.Wegener granulomatosis: an analysis of 158 patients.Ann Intern Med1992;116:48898.
  • 3
    Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al, for the RAVE-ITN Research Group.Rituximab versus cyclophosphamide for ANCA-associated vasculitis.N Engl J Med2010;363:22132.
  • 4
    Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB, et al, for the International Network for the Study of the Systemic Vasculitides (INSSYS).A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score.Arthritis Rheum2001;44:91220.
  • 5
    Specks U, Merkel PA, Hoffman GS, Langford CA, Spiera R, Seo P, et al, for the RAVE-ITN Research Group.Design of the Rituximab in ANCA-associated Vasculitis (RAVE) Trial.Open Arthritis J2011;4:118.
  • 6
    Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, et al.Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides.Arthritis Rheum1997;40:37180.
  • 7
    Damoiseaux J, Dahnrich C, Rosemann A, Probst C, Komorowski L, Stegeman CA, et al.A novel enzyme-linked immunosorbent assay using a mixture of human native and recombinant proteinase-3 significantly improves the diagnostic potential for antineutrophil cytoplasmic antibody-associated vasculitis.Ann Rheum Dis2009;68:22833.
  • 8
    National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v.3.2006. URL: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.
  • 9
    Stone JH, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, et al, and for the RAVE -ITN Research Group.Extended follow-up of treatment with rituximab versus cyclophosphamide for remission-induction of ANCA-associated vasculitis: which subsets are at greatest risk for flare? [abstract].Arthritis Rheum2011;63 Suppl:S9467.
  • 10
    Franssen C, Gans R, Kallenberg C, Hageluken C, Hoorntje S.Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificity: distinct differences between patients with anti-proteinase 3 and anti-myeloperoxidase autoantibodies.J Intern Med1998;244:20916.
  • 11
    Harper L, Morgan MD, Walsh M, Hoglund P, Westman K, Flossmann O.Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.Ann Rheum Dis2012;71:95560.
  • 12
    Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al, for the European Vasculitis Study Group.A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.N Engl J Med2003;349:3644.
  • 13
    Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, et al, for the French Vasculitis Study Group.Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.N Engl J Med2008;359:2790803.
  • 14
    Walsh M, Flossmann O, Berden A, Westman K, Hoglund P, Stegeman C, et al, on behalf of the European Vasculitis Study Group.Risk factors for relapse of antineutrophil cytoplasmic antibody–associated vasculitis.Arthritis Rheum2012;64:5428.
  • 15
    Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR, et al.Genetically distinct subsets within ANCA-associated vasculitis.N Engl J Med2012;367:21423.
  • 16
    Jones RB, Ferraro AJ, Chaudhry AN, Brogan P, Salama AD, Smith KG, et al.A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody–associated vasculitis.Arthritis Rheum2009;60:215668.
  • 17
    Vos K, Thurlings RM, Wijbrandts CA, van Schaardenburg D, Gerlag DM, Tak PP.Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis.Arthritis Rheum2007;56:7728.
  • 18
    Genberg H, Hansson A, Wernerson A, Wennberg L, Tyden G.Pharmacodynamics of rituximab in kidney allotransplantation.Am J Transplant2006;6:241828.
  • 19
    De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al, for the European Vasculitis Study Group.Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody–associated vasculitis.Arthritis Rheum2005;52:24619.
  • 20
    De Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, et al, EUVAS (European Vasculitis Study Group).Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.Ann Intern Med2009;150:67080.
  • 21
    Hiemstra TF, Walsh M, Mahr A, Savage CO, de Groot K, Harper L, et al, for the European Vasculitis Study Group (EUVAS).Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial.JAMA2010;304:23818.